Engineering immune cells to target senescent cells

What the research found

Researchers studied CAR T cells directed against uPAR, a surface marker associated with some senescent cells. In mice, the approach produced lasting effects on selected age-related metabolic and physical-function measures. The study explored the possibility that engineered immune cells could provide sustained senescent-cell targeting.

Where the evidence stops

These findings do not establish a safe anti-ageing CAR T treatment for people. Target specificity, persistence, unwanted immune effects and the diverse roles of senescent cells require careful investigation.

The private-client perspective

A personalised cell product can sound inherently precise, but personal manufacture does not guarantee selective action or an acceptable risk profile. A research review should explain the target, which healthy cells might share it and whether the intervention can be controlled after administration. Long-lived biological effects make long-term monitoring especially important.

Read the source

1. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. (2024-01-24)

An independent editorial synthesis of published research, not an original NoahThera study or a personal medical recommendation. Evidence stages are identified above; cited researchers and institutions are not represented as NoahThera partners.